- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Ibuzatrelvir
Setting: Primary care
The first level of healthcare, including general medical services, such as family medicine
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza-like illness/Acute respiratory infection
- Pharmacological intervention
- Antivirals
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Primary care
- Influenza-like illness/Acute respiratory infection
- Pharmacological intervention
- Telehealth
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- Respiratory syncytial virus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- Respiratory syncytial virus
- Influenza virus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus